DOXYCYCLINE by Novartis is mechanism of action doxycycline inhibits bacterial protein synthesis by binding to the 30s ribosomal subunit. Approved for the following infections: rocky mountain spotted fever, typhus fever, the typhus group and 8 more indications. First approved in 2006.
Drug data last refreshed 3h ago
Mechanism of Action Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. Doxycycline has bacteriostatic activity against a broad range of Gram-positive and Gram-negative bacteria. Resistance Cross resistance with other tetracyclines is common. Antimicrobial…
Worked on DOXYCYCLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Isotretinoin vs. Doxycycline for Acneiform Rash in Patients Receiving Drugs That Target the MAPK Pathway
Comparing Sarecycline and Doxycycline Effects on the Skin and Gut Bacteria in Acne.
Doxycycline vs. Macrolide for MRMP (DOMINO)
Doxycycline Prophylaxis for Prevention of Sexually Transmitted Infections
Weekly Doxycycline DOT for STI Prevention Among Cisgender Women Taking HIV PrEP in Kisumu, Kenya